Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Peritoneal Dialysis III: Nursing Management01:25

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Claudio Bordignon.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

Scientific reports·2026
Same author

A roadmap for supporting the development of advanced therapy medicinal products in a European framework.

The Lancet regional health. Europe·2026
Same author

The Homozygous p.(Arg215Ter) Variant in XRCC2 Is Associated With Atypical Fanconi Anemia Without Major Hematological Abnormalities in Childhood.

American journal of medical genetics. Part A·2026
Same author

Systematic review of hematopoietic stem cell transplantation in patients with ataxia telangiectasia: a case report and an individual patient-level analysis.

Frontiers in immunology·2026
Same author

Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jun 21, 2026

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme
04:17

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

Published on: September 27, 2024

How I treat ADA deficiency.

H Bobby Gaspar1, Alessandro Aiuti, Fulvio Porta

  • 1Centre for Immunodeficiency, Molecular Immunology Unit, University College London Institute of Child Health, London, United Kingdom. h.gaspar@ich.ucl.ac.uk

Blood
|July 30, 2009
PubMed
Summary

Adenosine deaminase deficiency (ADA-SCID) is a fatal genetic disorder requiring early intervention. Matched sibling transplants offer high survival, while enzyme replacement therapy and gene therapy provide excellent alternatives for ADA-SCID management.

More Related Videos

Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer
05:54

Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Jun 21, 2026

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme
04:17

Determining the Serum Stability of Human Adenosine Deaminase 1 Enzyme

Published on: September 27, 2024

Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer
05:54

Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer

Published on: May 10, 2024

Area of Science:

  • Immunology
  • Genetics
  • Metabolic Disorders

Background:

  • Adenosine deaminase deficiency causes severe combined immunodeficiency (ADA-SCID), a life-threatening condition.
  • Early intervention is crucial for survival in ADA-SCID patients.
  • Treatment options for ADA-SCID include hematopoietic stem cell transplantation (HSCT), enzyme replacement therapy (ERT), and gene therapy (GT).

Purpose of the Study:

  • To review current evidence and propose a consensus management strategy for ADA-SCID.
  • To evaluate the efficacy and outcomes of different treatment modalities for ADA-SCID.
  • To provide guidance on treatment selection based on available evidence and clinical experience.

Main Methods:

  • Literature review of existing evidence on ADA-SCID treatments.
  • Analysis of survival rates and immune recovery following different HSCT donor sources.
  • Evaluation of outcomes for enzyme replacement therapy (ERT) and gene therapy (GT).

Main Results:

  • Matched sibling donor HSCT demonstrates high survival rates and excellent immune recovery.
  • Mismatched parental donor HSCT is associated with poor survival and should be avoided.
  • ERT and GT offer excellent survival rates, presenting viable alternatives to HSCT.

Conclusions:

  • Treatment decisions for ADA-SCID should consider factors like treatment accessibility, patient response to ERT, and physician/parental preferences regarding risks.
  • A consensus management strategy is proposed to guide optimal treatment selection for ADA-SCID.
  • Further research may be needed to refine treatment guidelines due to the rarity of ADA-SCID and limited large-scale outcome studies.